A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098Nicholas F. Brown, Paul Mulholland, Graham Searle et al.|Neuro-Oncology|2018Cited by 83
A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors.Hendrik‐Tobias Arkenau, Li Yan, Ivana Rizzuto et al.|Journal of Clinical Oncology|2015Cited by 7
ATNT-06EVALUATION OF THE SAFETY OF GSK2256098 AND PHARMACOKINETICS OF<sup>11</sup>C-GSK2256098 IN PATIENTS WITH RECURRENT GLIOBLASTOMA BY POSITRON EMISSION TOMOGRAPHY (PET) IMAGINGPaul Mulholland, Sarah P. Blagden, Jianping Zhang et al.|Neuro-Oncology|2015Cited by 3